Baker & McKenzie has chosen Singapore partner Ashok Lalwani to head the firm’s global India practice. He succeeds David Jacobs, who led the practice since 2005 and is retiring as a partner of the firm.
Baker & McKenzie’s India practice includes over 300 lawyers worldwide, who advise Indian companies on outbound matters and multinational entities on their investments in India. Lalwani will spearhead this group.
The firm has won important India mandates over the years including as an adviser on Abbott Laboratories’ US$3.8 billion acquisition of Piramal Healthcare; Hospira and a subsidiary’s US$200 million acquisition of Orchid Chemicals & Pharmaceuticals’ active pharmaceutical ingredient manufacturing facility; and Coal India’s acquisition of a coal mine in Indonesia.
Lalwani joined Baker & McKenzie Wong & Leow as a partner in 2002. He has more than 23 years of experience advising financial institutions and companies on international securities, mergers and acquisitions, and general corporate law. He is also head of the firm’s Asia Pacific and US securities practices.
“India presents one of the best growth opportunities for business today, with strong economic fundamentals and burgeoning domestic consumption,” said Lalwani. “Our priority is to further assist our Indian clients with their global aspirations.”
“Ashok’s entrenched relationships with many of the Indian conglomerates and his strong cross-border transactional experience makes him a natural fit for this position,” said Eduardo Leite, chairman of Baker & McKenzie’s executive committee. “We thank David for his outstanding leadership and insight in building a pre-eminent India practice.”